ArriVent BioPharma (AVBP) Securities Investigation Notice - Levi & Korsinsky
ArriVent BioPharma shares lost more than half their value after the pivotal Phase 3 FURVENT trial of lead candidate firmonertinib missed its primary endpoint. An investigation into potential securities law violations is underway on behalf of AVBP investors. NEW YORK, Oct. 13, 2026...